Predictors of Improved Outcomes in the Management of Newly Diagnosed Glioblastoma Multiforme – Retrospective Review of a Single Centre Experience. (1st October 2022)
- Record Type:
- Journal Article
- Title:
- Predictors of Improved Outcomes in the Management of Newly Diagnosed Glioblastoma Multiforme – Retrospective Review of a Single Centre Experience. (1st October 2022)
- Main Title:
- Predictors of Improved Outcomes in the Management of Newly Diagnosed Glioblastoma Multiforme – Retrospective Review of a Single Centre Experience
- Authors:
- Ziff, Charlotte
Price, Louise
Elmasry, Abdelfattah
Giridharan, Selvaraj - Abstract:
- Abstract: AIMS: To assess the benefit of combining maximal resection, Gliadel wafer insertion, CCRT and 4 or more cycles of adjuvant TMZ. METHOD: We retrospectively reviewed a cohort of 110 patients who had undergone neurosurgery followed by chemo-radiotherapy (CRT) 60 Gray in 30 fractions and had at least one cycle of adjuvant TMZ from 2007 to 2016. Minimum follow up period 5 years. RESULTS: Patients who had maximal safe debulking plus Gliadel wafer insertion, median OS was 19.5 months (95% confidence interval 14-30) those without wafers median OS was 16 months (95% confidence interval 14 – 21), P=0.06; significant on cox regression modelling. (P-value 0.008). Those continuing to receive at least 4 cycles of adjuvant TMZ median OS improved by 10 months compared to those unable to complete 4 cycles (10 vs 20 months). On cox analysis the number of adjuvant cycles of TMZ significantly affects OS, P-value 0.0003. Of these significant predictors of OS when combined (n=12) median OS was 18 months. Compared to 16 months for those who did not receive Glidel wafers and could not complete 4 cycles of TMZ following CRT. OS log-rank test P-value 0.4 CONCLUSION: We were not able to demonstrate a statistically significant improved OS for those undergoing wafer insertion and completing at least 4 cycles of TMZ. Data may be inconclusive due to the small numbers, we conclude standard of care should still remain maximal safe debulking followed by CCRT and TMZ.
- Is Part Of:
- Neuro-oncology. Volume 24(2022)Supplement 4
- Journal:
- Neuro-oncology
- Issue:
- Volume 24(2022)Supplement 4
- Issue Display:
- Volume 24, Issue 4 (2022)
- Year:
- 2022
- Volume:
- 24
- Issue:
- 4
- Issue Sort Value:
- 2022-0024-0004-0000
- Page Start:
- iv22
- Page End:
- iv22
- Publication Date:
- 2022-10-01
- Subjects:
- Brain Neoplasms -- Periodicals
Brain -- Tumors -- Periodicals
Brain -- Cancer -- Periodicals
Nervous system -- Cancer -- Periodicals
616.99481 - Journal URLs:
- http://neuro-oncology.dukejournals.org/ ↗
http://neuro-oncology.oxfordjournals.org/ ↗
http://www.oxfordjournals.org/content?genre=journal&issn=1522-8517 ↗
http://ukcatalogue.oup.com/ ↗ - DOI:
- 10.1093/neuonc/noac200.101 ↗
- Languages:
- English
- ISSNs:
- 1522-8517
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6081.288000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24109.xml